Drugs / BEBT-209
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06047184 | Jul 2019 → Oct 2023 | female breast carcinoma | BeBetter Med Inc | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06685796 | Apr 2023 → Jun 2026 overdue | triple-negative breast carcinoma | BeBetter Med Inc | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07544056 | Apr 2026 → Jun 2030 expected | triple-negative breast carcinoma | BeBetter Med Inc | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06998108 Comparator | Jun 2022 → Dec 2025 overdue | hormone receptor-positive breast cancer | BeBetter Med Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEBT-209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998108 ↗ |
| Action | Inhibit | “BEBT-209 acts as a highly selective CDK4/6 inhibitor” NCT07544056 ↗ |
| Route | Oral | “take orally once before dinner or twice (before breakfast and before dinner)” NCT06685796 ↗ |
| Target | CDK4 | “BEBT-209 acts as a highly selective CDK4/6 inhibitor” NCT07544056 ↗ |